RecruitingPhase 1NCT06995625

The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)

An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke

Sponsor

S&Ebio Co. Ltd.

Enrollment

18 participants

Start Date

Jun 22, 2026

Study Type

INTERVENTIONAL

Conditions

Acute Ischemic Stroke AIS

Summary

This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SNE-101 for people with acute ischemic stroke ais. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSNE-101

Experimental: Cohort 1 - SNE-101 4.8 × 10e10 particles (n=3 to 6) Experimental: Cohort 2 - SNE-101 9.6 × 10e10 particles (n=3 to 6) Experimental: Cohort 3 - SNE-101 19.2 × 10e10 particles (n=3 to 6)